Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Genelux Corp. (GNLX) Stock Price & Analysis

GNLX Stock Chart & Stats

$2.08-$0.02(-0.95%)
At close: 4:00 PM EDT
$2$2.5$33 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
$2.00 - $2.11
52-Week Range
$1.86 - $8.54
Previous Close
$2.10
Volume
44.18K
Average Volume (3M)
351.87K
Market Cap
$94.11M
Enterprise Value
$119.08M
Total Cash (Recent Filing)
$18.67M
Total Debt (Recent Filing)
$2.42M
Price to Earnings (P/E)
―
Beta
1.31
Next Earnings
Nov 18, 2026 (Est.)
EPS Estimate
-0.2
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Oncology Platform

Genelux has a differentiated proprietary asset rather than only an undifferentiated research program. Clinical evaluation of Olvi-Vec creates the potential to validate the platform, support future partnering, and build a broader oncology franchise if development succeeds.

Multi-indication Pipeline

The pipeline is not limited to a single cancer setting or treatment approach. Exploring multiple indications and combinations gives Genelux several potential development paths, which can diversify clinical opportunities and increase the strategic value of its viral immunotherapy platform.

Modest Leverage

Relatively low reported leverage reduces the burden of debt service compared with a highly indebted development-stage company. This provides some balance-sheet flexibility while Genelux advances its clinical programs, although it does not eliminate the need for additional funding.

Bears Say

Minimal Commercial Revenue

Genelux has not yet demonstrated a commercial revenue base capable of supporting operations. Near-zero revenue alongside very large operating and net losses leaves the company dependent on successful clinical and regulatory progress before a sustainable product-based business can emerge.

Heavy Cash Burn

Substantial operating and free-cash-flow deficits show that Genelux is not self-funding its research and clinical activities. Continued cash consumption increases the importance of external financing and can constrain development plans if capital becomes less available or more costly.

Dilution And Recapitalization Risk

Past balance-sheet volatility indicates that ongoing losses have previously placed pressure on the capital structure. If cash burn continues, future equity issuance or recapitalization may be required, potentially diluting existing holders and limiting financial flexibility.

Genelux Corp. News

GNLX FAQ

What was Genelux Corp.’s price range in the past 12 months?
Genelux Corp. lowest stock price was $1.86 and its highest was $8.54 in the past 12 months.
What is Genelux Corp.’s market cap?
Genelux Corp.’s market cap is $94.11M.
When is Genelux Corp.’s upcoming earnings report date?
Genelux Corp.’s next earnings report is estimated for Nov 18, 2026 (not yet confirmed), which is in 16 days.
How were Genelux Corp.’s earnings last quarter?
Genelux Corp. released its earnings results on Aug 13, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.197 by -$0.013.
Is Genelux Corp. overvalued?
According to Wall Street analysts Genelux Corp.’s price is currently Undervalued.
Does Genelux Corp. pay dividends?
Genelux Corp. does not currently pay dividends.
What is Genelux Corp.’s EPS estimate?
Genelux Corp.’s EPS estimate is -0.20.
How many shares outstanding does Genelux Corp. have?
Genelux Corp. has 45,245,335 shares outstanding.
What happened to Genelux Corp.’s price movement after its last earnings report?
Genelux Corp. reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.197. Following the earnings report the stock price went up 4.183%.
Which hedge fund is a major shareholder of Genelux Corp.?
Hedge funds hold Genelux Corp. shares: the largest hedge-fund position in Genelux Corp. is 71,885,045 shares, and hedge funds increased their holdings by 33.7K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology